Nxera Pharma Co., Ltd.

4565

JP3431300007

Pharmaceuticals

Delayed Japan Exchange Other stock markets 08:00:00 08/07/2025 am IST			5-day change	1st Jan Change
850.00 ^JPY	-0.58%		-3.85%	-18.89%

04/07	Nxera Pharma to Receive USD 4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 Agonist	CI
04/07	Nxera Pharma to Receive $4.8 Million in Milestone Payments from Centessa	MT

Nxera Pharma Gets $15 Million Milestone Payment as Schizophrenia Drug Enters Phase 3

Published on 03/06/2025 at 17:58

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Nxera Pharma Co., Ltd.

Nxera Pharma to Receive USD 4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 Agonist	04/07	CI
Nxera Pharma to Receive $4.8 Million in Milestone Payments from Centessa	04/07	MT
Nxera Pharma Gets $15 Million Milestone Payment as Schizophrenia Drug Enters Phase 3	03/06	MT
Nxera Pharma to Receive USD 15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568	03/06	CI
Japanese Shares Fall as Trump Threatens Higher Steel and Aluminium Tariffs	02/06	MT
Nxera Pharma Hits Diabetes & Metabolic Disease Milestone with Eli Lilly	02/06	MT
Nxera Pharma Co Ltd - Nxera Pharma Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases	02/06	RE
Nxera Pharma Says Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases	02/06	RE
Nxera Pharma Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025	29/05	CI
Weight-loss drug developers line up to tap lucrative market as competition heats up	16/05	RE
Nxera Pharma Co., Ltd. Appoints Shinya Tsuzuki as Head of Investor Relations	02/05	CI
Nxera Pharma Co., Ltd. Announces Board Appointments	02/05	CI
Neurocrine Biosciences Launches Phase 3 Trial for Schizophrenia Drug NBI-1117568	02/05	MT
Nxera Pharma Co., Ltd Announces Executive Changes, Effective April 1,2025	01/04	CI
Jefferies Adjusts Nxera Pharma's Price Target to 2,000 Yen From 2,100 Yen, Keeps at Buy	12/03	MT
Nxera Pharma Enters Agreement with Holling Bio-Pharma Corp. to Commercialize Daridorexant in Taiwan	28/02	CI
Nxera Pharma Assigns Japan and Apac (Ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris	28/02	CI
Nxera Pharma Co., Ltd., 2024 Earnings Call, Feb 14, 2025	14/02
Nxera Pharma Co., Ltd. Announces Board Changes	14/02	CI
Nxera Pharma Co., Ltd. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:00 PM	16/01
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea	05/12	CI
Nikkei Slips as Beijing's Property Support Measures Fail to Lift Sentiment	14/11	MT
Nxera Pharma's Partner Centessa Launches Phase 2 Trial of ORX750	14/11	MT
Nxera Pharma Co., Ltd. - Special Call	06/11
Nxera Pharma and Antiverse Enter Collaboration to Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI	05/11	CI

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Employees

387

Sector

Pharmaceuticals

Calendar

08/08 - Q2 2025 Earnings Release

More about the company